BACKGROUND: An 85-year-old man developed faint crystallike white precipitates in the mid peripheral stroma of his left cornea 3 weeks after undergoing penetrating keratoplasty. The patient had been initially treated with 1% prednisolone acetate ophthalmic suspension and 0.3% gatifloxacin eyedrops to his left eye from the first day postoperatively. Three weeks later, the precipitates were more numerous, larger, and diffuse in distribution. Gatifloxacin was discontinued and substituted with a neomycin-polymixin B-dexamethasone ophthalmic ointment. METHODS: A detailed history, physical examination, laboratory workup, and tandem scanning confocal microscopy were performed. RESULTS: Tandem scanning corneal confocal microscopy confirmed the presence of crystals in the cornea. CONCLUSIONS: Gatifloxacin, a fourth-generation fluoroquinolone, can cause intrastromal macroscopic crystalline deposits through a compromised corneal epithelium, similar to what has been described for ciprofloxacin, a second-generation fluoroquinolone.
BACKGROUND: An 85-year-old man developed faint crystallike white precipitates in the mid peripheral stroma of his left cornea 3 weeks after undergoing penetrating keratoplasty. The patient had been initially treated with 1% prednisolone acetate ophthalmic suspension and 0.3% gatifloxacin eyedrops to his left eye from the first day postoperatively. Three weeks later, the precipitates were more numerous, larger, and diffuse in distribution. Gatifloxacin was discontinued and substituted with a neomycin-polymixin B-dexamethasone ophthalmic ointment. METHODS: A detailed history, physical examination, laboratory workup, and tandem scanning confocal microscopy were performed. RESULTS: Tandem scanning corneal confocal microscopy confirmed the presence of crystals in the cornea. CONCLUSIONS:Gatifloxacin, a fourth-generation fluoroquinolone, can cause intrastromal macroscopic crystalline deposits through a compromised corneal epithelium, similar to what has been described for ciprofloxacin, a second-generation fluoroquinolone.
Authors: I Livingstone; F Stefanowicz; S Moggach; J Connolly; S Ramamurthi; S Mantry; K Ramaesh Journal: Eye (Lond) Date: 2013-04-05 Impact factor: 3.775